AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17385120 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary eye muscle surgery on 2 horizontal muscles
Number of subjects: 32
Study 17385120 — intervention group
Group type: EXPERIMENTAL
Intervention: Revision surgeries on 2 horizontal muscles
Number of subjects: 32
Study 17385120 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary eye muscle surgeries on 2 vertical recti
Number of subjects: 32
Study 15473523 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation (2 mg/kg/day)
Number of subjects: 100
Study 15473523 — intervention group
Group type: COMPARATOR
Intervention: Placebo drops
Number of subjects: 100
Study 11359489 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 5 mg/ml
Number of subjects: 18
Study 11359489 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 7.5 mg/ml
Number of subjects: 18
Study 11359489 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 2% + epinephrine 1:80,000
Number of subjects: 18
Study 11359489 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 18
Study 9496328 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (i.v.) administration of 10,000 IU recombinant human LH
Number of subjects: 12
Study 9496328 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular (i.m.) administration of 10,000 IU recombinant human LH
Number of subjects: 12
Study 9496328 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous (s.c.) administration of 10,000 IU recombinant human LH
Number of subjects: 12
Study 7993988 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated tablet (EC)
Number of subjects: 113
Study 7993988 — intervention group
Group type: COMPARATOR
Intervention: Plain capsule (PC)
Number of subjects: 113
Study 2789363 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponsinomycin 400 mg
Number of subjects: 12
Study 2789363 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponsinomycin 800 mg
Number of subjects: 12
Study 2789363 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponsinomycin 1200 mg
Number of subjects: 12
Study 4157126 — intervention group
Group type: EXPERIMENTAL
Intervention: sotalol
Number of subjects: 146
Study 4157126 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 146
Study 29127558 — intervention group
Group type: EXPERIMENTAL
Intervention: Perineural dexamethasone (4 mg)
Number of subjects: 280
Study 29127558 — intervention group
Group type: EXPERIMENTAL
Intervention: Perineural dexamethasone (8 mg)
Number of subjects: 280
Study 29127558 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone (4 mg)
Number of subjects: 280
Study 29127558 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone (8 mg)
Number of subjects: 280
Study 29127558 — intervention group
Group type: COMPARATOR
Intervention: Perineural dexamethasone (4 mg) vs Intravenous dexamethasone (4 mg)
Number of subjects: 280
Study 29127558 — intervention group
Group type: COMPARATOR
Intervention: 8 mg vs 4 mg dexamethasone
Number of subjects: 280
Study 28259777 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide (25 mg), rilpivirine (25 mg), emtricitabine (200 mg)
Number of subjects: 630
Study 28259777 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate (300 mg), rilpivirine (25 mg), emtricitabine (200 mg)
Number of subjects: 630
Study 28259777 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide
Number of subjects: 630
Study 28259777 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate
Number of subjects: 630
Study 26497961 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 38
Study 26497961 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 38
Study 26497961 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 38
Study 26497961 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 38
Study 26497961 — intervention group
Group type: COMPARATOR
Intervention: No rate control drug (baseline)
Number of subjects: 38
Study 22038082 — intervention group
Group type: EXPERIMENTAL
Intervention: Good parole officer-parolee relationships
Number of subjects: 374
Study 20926554 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory-based intervention
Number of subjects: 484
Study 20926554 — intervention group
Group type: COMPARATOR
Intervention: Information-only control
Number of subjects: 484
Study 18506924 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic Lactobacillus rhamnosus GG (LGG)
Number of subjects: 26
Study 18506924 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 26
Study 17323614 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg or Simvastatin 40 mg
Number of subjects: 46
Study 17323614 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of statin + 200 mg micronized fenofibrate
Number of subjects: 46
Study 17323614 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin + 3.6 g n-3 polyene fatty acids (PUFA n-3)
Number of subjects: 46
Study 17323614 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 46
Study 14664413 — intervention group
Group type: EXPERIMENTAL
Intervention: Climex (5 chewable tablets daily between meals)
Number of subjects: 55
Study 14664413 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 10760307 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy plus hematopoietic stem cells
Number of subjects: 553
Study 10760307 — intervention group
Group type: COMPARATOR
Intervention: Conventional-dose chemotherapy
Number of subjects: 553
Study 8622391 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg once daily)
Number of subjects: 96
Study 8622391 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 1396292 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonographically measured biparietal diameter (BPD) in the second trimester
Number of subjects: 4997
Study 1396292 — intervention group
Group type: COMPARATOR
Intervention: Gestational age estimated from last menstrual period (LMP)
Number of subjects: 4997
Study 3928320 — intervention group
Group type: EXPERIMENTAL
Intervention: 1g temocillin
Number of subjects: 26
Study 3928320 — intervention group
Group type: EXPERIMENTAL
Intervention: 2g temocillin
Number of subjects: 26
Study 31331836 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Health Centre (CHC)
Number of subjects: 188
Study 31331836 — intervention group
Group type: COMPARATOR
Intervention: Emergency Department (ED)
Number of subjects: 188
Study 29720370 — intervention group
Group type: EXPERIMENTAL
Intervention: Low serum 25(OH)D concentrations (<25 nmol/L)
Number of subjects: 854
Study 27454372 — intervention group
Group type: EXPERIMENTAL
Intervention: Drinker Inventory of Consequences (DrInC) categories
Number of subjects: 952
Study 27454372 — intervention group
Group type: EXPERIMENTAL
Intervention: DrInC categories
Number of subjects: 952
Study 27454372 — intervention group
Group type: EXPERIMENTAL
Intervention: DrInC trajectories
Number of subjects: 952
Study 27454372 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intercepts during treatment
Number of subjects: 952
Study 27454372 — intervention group
Group type: EXPERIMENTAL
Intervention: Steeper negative slopes
Number of subjects: 952
Study 27454372 — intervention group
Group type: EXPERIMENTAL
Intervention: Relationships between trajectories and drinking behavior
Number of subjects: 952
Study 23786310 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm formula or mother's own milk (random allocation to raw or pasteurized milk)
Number of subjects: 150
Study 23786310 — intervention group
Group type: EXPERIMENTAL
Intervention: Intestinal colonization with staphylococci
Number of subjects: 150
Study 23786310 — intervention group
Group type: EXPERIMENTAL
Intervention: Intestinal colonization
Number of subjects: 150
Study 22316732 — intervention group
Group type: EXPERIMENTAL
Intervention: Aesthetic system at 100% accuracy
Number of subjects: 0
Study 22316732 — intervention group
Group type: EXPERIMENTAL
Intervention: Aesthetic system at 85% accuracy
Number of subjects: 0
Study 22316732 — intervention group
Group type: COMPARATOR
Intervention: Non-aesthetic system at 100% accuracy
Number of subjects: 0
Study 22316732 — intervention group
Group type: COMPARATOR
Intervention: Non-aesthetic system at 85% accuracy
Number of subjects: 0
Study 20450603 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative (125)I seed implantation (group A)
Number of subjects: 298
Study 20450603 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (group B)
Number of subjects: 298
Study 17077322 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line polychemotherapy (n = 44)
Number of subjects: 48
Study 17077322 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (n = 4)
Number of subjects: 48
Study 17077322 — intervention group
Group type: COMPARATOR
Intervention: Absence of PI9 expression
Number of subjects: 48
Study 17077322 — intervention group
Group type: COMPARATOR
Intervention: Low apoptotic index
Number of subjects: 48
Study 15605857 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoustic-based method for classifying swallowing sounds
Number of subjects: 26
Study 15605857 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dysphagia)
Number of subjects: 26
Study 15605857 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with dysphagia
Number of subjects: 26
Study 11731725 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT) with bilateral electrode placement at 50% above the titrated seizure threshold
Number of subjects: 253
Study 11731725 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 253
Study 9142008 — intervention group
Group type: EXPERIMENTAL
Intervention: AS-013 (prostaglandin E1 prodrug) administered by intravenous injection 5 d/wk for 4 weeks
Number of subjects: 80
Study 9142008 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 7956270 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon laser trabeculoplasty (ALT) followed by trabeculectomy, and a second trabeculectomy if needed
Number of subjects: 591
Study 7956270 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy followed by ALT, and a second trabeculectomy if needed
Number of subjects: 591
Study 7956270 — intervention group
Group type: EXPERIMENTAL
Intervention: Both sequences of surgical treatments
Number of subjects: 591
Study 3230146 — intervention group
Group type: EXPERIMENTAL
Intervention: A-56234 at 20 mg
Number of subjects: 24
Study 3230146 — intervention group
Group type: EXPERIMENTAL
Intervention: A-56234 at 40 mg
Number of subjects: 24
Study 3230146 — intervention group
Group type: EXPERIMENTAL
Intervention: A-56234 at 60 mg
Number of subjects: 24
Study 3230146 — intervention group
Group type: EXPERIMENTAL
Intervention: A-56234 at 80 mg
Number of subjects: 24
Study 3230146 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 30005743 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (lipophilic)
Number of subjects: 10
Study 30005743 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin (hydrophilic)
Number of subjects: 10
Study 26759468 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counseling
Number of subjects: 0
Study 26759468 — intervention group
Group type: COMPARATOR
Intervention: In-person counseling
Number of subjects: 0
Study 26759468 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 0
Study 25788517 — intervention group
Group type: EXPERIMENTAL
Intervention: Video counseling
Number of subjects: 40
Study 25788517 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face counseling
Number of subjects: 40
Study 23594858 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclosporin (CSA)
Number of subjects: 148
Study 23594858 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus (TAC)
Number of subjects: 148
Study 20873905 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 79
Study 20873905 — intervention group
Group type: COMPARATOR
Intervention: Progressive Relaxation Training (PRT)
Number of subjects: 79
Study 18297975 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy trials
Number of subjects: 237
Study 18297975 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy trials
Number of subjects: 237
Study 18297975 — intervention group
Group type: COMPARATOR
Intervention: Comparison of psychotherapy and pharmacotherapy trials
Number of subjects: 237
Study 16802855 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone 0.2 mg/kg buccally
Number of subjects: 30
Study 16802855 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone 0.2 mg/kg sublingually
Number of subjects: 30
Study 14711140 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular alefacept 15 mg
Number of subjects: 0
Study 14711140 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alefacept
Number of subjects: 0
Study 10836009 — intervention group
Group type: EXPERIMENTAL
Intervention: Curative treatment for hepatic malignancies
Number of subjects: 0
Study 10836009 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational therapies for hepatic malignancies
Number of subjects: 0
Study 9190980 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene
Number of subjects: 69
Study 9190980 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 9190980 — intervention group
Group type: COMPARATOR
Intervention: Beta-carotene and Placebo
Number of subjects: 69
Study 9190980 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-high-risk HPV types
Number of subjects: 69
Study 9190980 — intervention group
Group type: EXPERIMENTAL
Intervention: Age <25 years
Number of subjects: 69
Study 9190980 — intervention group
Group type: EXPERIMENTAL
Intervention: Douching after sexual intercourse
Number of subjects: 69
Study 1565349 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen, 600 mg
Number of subjects: 16
Study 1565349 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 6323378 — intervention group
Group type: EXPERIMENTAL
Intervention: Pivmecillinam
Number of subjects: 64
Study 6323378 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-trimoxazole
Number of subjects: 64
Study 6323378 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral mecillinam
Number of subjects: 64
Study 6323378 — intervention group
Group type: COMPARATOR
Intervention: Supportive care only (Control)
Number of subjects: 64
Study 31373188 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone heart rate monitoring application
Number of subjects: 24
Study 29525763 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates once a week (PG1)
Number of subjects: 296
Study 29525763 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates twice a week (PG2)
Number of subjects: 296
Study 29525763 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates three times a week (PG3)
Number of subjects: 296
Study 29525763 — intervention group
Group type: COMPARATOR
Intervention: Booklet group (BG)
Number of subjects: 296
Study 29525763 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates twice a week (PG2) vs Pilates once a week (PG1)
Number of subjects: 296
Study 27154357 — intervention group
Group type: EXPERIMENTAL
Intervention: LY + SUN (LY2510924 20 mg SC daily + Sunitinib 50 mg PO daily for 4 weeks followed by 2 weeks off)
Number of subjects: 108
Study 27154357 — intervention group
Group type: COMPARATOR
Intervention: SUN (Sunitinib 50 mg PO daily for 4 weeks followed by 2 weeks off)
Number of subjects: 108
Study 25978321 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in the correct use of a satiety labelled magnitude scale (LMS)
Number of subjects: 23
Study 25978321 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard breakfast with 5g of viscous fibre
Number of subjects: 23
Study 22033810 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonic stenting followed by elective surgery
Number of subjects: 39
Study 22033810 — intervention group
Group type: COMPARATOR
Intervention: Emergency surgery
Number of subjects: 39
Study 20232413 — intervention group
Group type: EXPERIMENTAL
Intervention: BMT resection
Number of subjects: 242
Study 20232413 — intervention group
Group type: COMPARATOR
Intervention: BMT preservation
Number of subjects: 242
Study 18547433 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03%
Number of subjects: 65
Study 18547433 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost 0.005%
Number of subjects: 65
Study 15876347 — intervention group
Group type: EXPERIMENTAL
Intervention: Racemic epinephrine
Number of subjects: 62
Study 15876347 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol
Number of subjects: 62
Study 15876347 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 62
Study 11808937 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial phlebotomy to reduce serum ferritin levels to 10 ng/ml or less followed by maintenance phlebotomy for 5 years
Number of subjects: 25
Study 11808937 — intervention group
Group type: COMPARATOR
Intervention: Control group (virological nonresponders to interferon)
Number of subjects: 25
Study 10411862 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin alone
Number of subjects: 919
Study 10411862 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin + warfarin combination
Number of subjects: 919
Study 10411862 — intervention group
Group type: COMPARATOR
Intervention: Warfarin alone
Number of subjects: 919
Study 8635022 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipiodol-epirubicin (75 mg/m2)
Number of subjects: 95
Study 8635022 — intervention group
Group type: COMPARATOR
Intervention: Lipiodol-131I (750-1050 MBq)
Number of subjects: 95
Study 2073669 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin (final average dose 70.5 mg/day)
Number of subjects: 40
Study 2073669 — intervention group
Group type: COMPARATOR
Intervention: Bezafibrate (400 mg/day)
Number of subjects: 40
Study 6845976 — intervention group
Group type: EXPERIMENTAL
Intervention: THIP (4,5,6,7‐tetrahydroisoxazolo(5,4‐c)pyridin‐3‐ol) at doses of 15 to 120 mg/day
Number of subjects: 9
Study 6845976 — intervention group
Group type: EXPERIMENTAL
Intervention: THIP (submaximal doses)
Number of subjects: 9
Study 6845976 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 31439091 — intervention group
Group type: EXPERIMENTAL
Intervention: Deproteinization with chlorine dioxide (ClO₂)
Number of subjects: 0
Study 31439091 — intervention group
Group type: EXPERIMENTAL
Intervention: Deproteinization with sodium hypochlorite (NaOCl)
Number of subjects: 0
Study 31439091 — intervention group
Group type: COMPARATOR
Intervention: Nontreated controls
Number of subjects: 0
Study 29562558 — intervention group
Group type: EXPERIMENTAL
Intervention: Chin tuck against resistance exercise (CTAR)
Number of subjects: 22
Study 29562558 — intervention group
Group type: COMPARATOR
Intervention: Conventional dysphagia treatment
Number of subjects: 22
Study 27627193 — intervention group
Group type: EXPERIMENTAL
Intervention: Omarigliptin 10 mg
Number of subjects: 8
Study 27627193 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 24724807 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose folic acid (5 mg/day)
Number of subjects: 28
Study 24724807 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 22998754 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (25 μg per day as cholecalciferol)
Number of subjects: 77
Study 22998754 — intervention group
Group type: COMPARATOR
Intervention: Placebo (25 μg per day as lactose)
Number of subjects: 77
Study 21051846 — intervention group
Group type: EXPERIMENTAL
Intervention: Gynoflor® (lyophilized lactobacilli and 0.03 mg estriol)
Number of subjects: 46
Study 21051846 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole (500 mg vaginal suppositories)
Number of subjects: 46
Study 17417917 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole (RPZ) 20 mg daily plus Clarithromycin (Cla) 500 mg b.d. and Amoxicillin (Am) 1,000 mg b.d. for 7 days
Number of subjects: 59
Study 17417917 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole (RPZ) 20 mg daily plus Clarithromycin (Cla) 500 mg b.d. and Amoxicillin (Am) 1,000 mg b.d. for 14 days
Number of subjects: 59
Study 16756030 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 57
Study 16756030 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 57
Study 15244246 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with cyclophosphamide, methotrexate, or 5-fluorouracil (CMF)
Number of subjects: 0
Study 15244246 — intervention group
Group type: COMPARATOR
Intervention: Postoperative radiotherapy
Number of subjects: 0
Study 15244246 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0
Study 15244246 — intervention group
Group type: COMPARATOR
Intervention: No endocrine treatment
Number of subjects: 0
Study 11031403 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 week of antibiotics and a chemical matrixectomy simultaneously (group 1)
Number of subjects: 54
Study 11031403 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics for 1 week and then a matrixectomy (group 2)
Number of subjects: 54
Study 11031403 — intervention group
Group type: COMPARATOR
Intervention: Matrixectomy alone (group 3)
Number of subjects: 54
Study 8833520 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant-retained mandibular overdenture (IRO)
Number of subjects: 151
Study 8833520 — intervention group
Group type: COMPARATOR
Intervention: Conventional complete denture (CD)
Number of subjects: 151
Study 1484915 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen (E)
Number of subjects: 19
Study 1484915 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 19
Study 2869001 — intervention group
Group type: EXPERIMENTAL
Intervention: atenolol 100 mg once a day
Number of subjects: 66
Study 2869001 — intervention group
Group type: EXPERIMENTAL
Intervention: oxprenolol 80 mg twice a day
Number of subjects: 66
Study 2869001 — intervention group
Group type: EXPERIMENTAL
Intervention: nadolol 80 mg once a day
Number of subjects: 66
Study 30324553 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir Disoproxil Fumarate (TDF) plus Peginterferon Alfa-2a
Number of subjects: 0